Zoledronic acid use in cancer patients: more than just supportive care? (Q37828494)

24 August 2017

1 reference

title

Zoledronic acid use in cancer patients: more than just supportive care? (English)

1 reference

24 August 2017

1 reference

Robert Coleman

1

1 reference

24 August 2017

Richard Cook

2

1 reference

24 August 2017

Vera Hirsh

3

1 reference

24 August 2017

Pierre Major

4

1 reference

24 August 2017

Allan Lipton

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

117

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

11-23

1 reference

Bisphosphonates: clinical experience

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Variation in the use of chemotherapy in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Optimal management of metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Antitumor effects of bisphosphonates: promising preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Preclinical pharmacology of zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Immunosurveillance and immunoregulation by gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Practical guidance for the management of aromatase inhibitor-associated bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Meta-analysis of clodronate and breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

The role of bisphosphonates in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25529

7 January 2021

Identifiers

DOI

10.1002/CNCR.25529

1 reference

24 August 2017

1 reference